The potential for IS by JAK3 inhibitors was discovered serendipitously by the observation gamma-chain mutations of JAK3 were associated with severe combined immunodeficiency in humans, a condition associated with non functional B cells and an absence of T cells and natural killer (NK) cells. The gene discussed is JAK3; the disease is severe combined immunodeficiency.